Vivos Therapeutics Inc Ordinary Shares VVOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VVOS is a good fit for your portfolio.
News
-
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
-
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
-
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
-
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
-
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
-
Vivos Therapeutics Shares More than Double on FDA's 510(k) Clearance for Sleep Apnea Treatment
Trading Information
- Previous Close Price
- $2.46
- Day Range
- $2.48–2.58
- 52-Week Range
- $2.37–48.79
- Bid/Ask
- $2.45 / $2.58
- Market Cap
- $7.40 Mil
- Volume/Avg
- 53,954 / 200,431
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.24
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an advanced therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by our company and prescribed by specially trained dentists in cooperation with their medical colleagues.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 114
- Website
- https://www.vivos.com
Valuation
|
Metric
|
VVOS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 11.87 |
Price/Sales | 0.24 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VVOS
|
|---|---|
Quick Ratio | 0.25 |
Current Ratio | 0.34 |
Interest Coverage | — |
Quick Ratio
VVOS
Profitability
|
Metric
|
VVOS
|
|---|---|
Return on Assets (Normalized) | −123.86% |
Return on Equity (Normalized) | −566.10% |
Return on Invested Capital (Normalized) | −320.04% |
Return on Assets
VVOS
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Ldpcwzbs | Vfhtt | $185.4 Bil | |
SYK
| Stryker Corp | Dmhwzpvwp | Pvy | $128.2 Bil | |
BSX
| Boston Scientific Corp | Kqrlynnl | Ldpvcv | $107.7 Bil | |
MDT
| Medtronic PLC | Fgpbqqhh | Wyykyg | $105.2 Bil | |
DXCM
| DexCom Inc | Hqzfxcmzzg | Rjy | $54.7 Bil | |
EW
| Edwards Lifesciences Corp | Rjmqqvdf | Zmxqgkp | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Kdrzqshm | Xtxk | $24.6 Bil | |
ALGN
| Align Technology Inc | Hkvdnrlf | Fyfwtry | $23.4 Bil | |
PHG
| Koninklijke Philips NV ADR | Ryrgbytj | Gzyjcbk | $18.7 Bil | |
PODD
| Insulet Corp | Lsgfllwc | Mnbbxx | $11.5 Bil |